Search Results for “NHS” – media

Eisai’s Leqembi deemed too costly for NHS

Though the UK became the first country in Europe to authorize use of Eisai and Biogen’s early Alzheimer’s disease drug, Leqembi (lecanemab), patients in the UK’s National Health Services (NHS) will not gain access to the drug as the anti-amyloid treatment was deemed too costly. As per the 22 August draft guidance consultation released by the National Institute for Health and Care Excellence (NICE), an independent committee found that the cost effectiveness estimates were “considerably above what NICE considers an acceptable use of NHS resources.” The committee cited a lack of evidence on the long-term effects of treatment with Leqembi and the costs of providing treatment infusions, monitoring side effects, and determining when to terminate treatment as uncertainties. According to the guidance, NICE has requested additional information from Eisai and NHS England to address the uncertainties and will consider the additional information alongside stakeholder comments in a second meeting. In ...
- Source: drugdu
- 69
- August 26, 2024
NHS Scotland, AZ and Scottish universities partner for kidney health research

NHS Scotland, AstraZeneca (AZ) and the Universities of Glasgow and Dundee have entered into a partnership to accelerate research into treating chronic kidney disease (CKD). The collaboration aims to develop new medicines to slow down the progression of CKD, build infrastructure and enhance expertise in renal clinical trial delivery in Scotland to improve patient outcomes. Affecting nearly 850 million people worldwide, CKD is a serious, progressive condition caused by decreased kidney function, commonly caused by diabetes, hypertension and glomerulonephritis. By preventing the progression of CKD, patients will live longer, better lives, free from other consequences of the condition, including heart failure, cardiovascular disease and stroke, while also reducing pressure on the NHS. In addition to slowing the progression of CKD, NHS Scotland, AZ and the Universities of Glasgow and Dundee will work to reduce the risk of patients potentially needing dialysis, a procedure to remove waste products and excess fluid ...
- Source: drugdu
- 107
- August 3, 2024
Study finds Parkinson’s disease SLT more effective than one used in NHS

The progressive neurodegenerative condition affects around 153,000 people in the UK Researchers from the Universities of Nottingham and Birmingham have revealed that a new form of speech therapy was more effective than the speech and language therapy (SLT) currently used in the NHS for Parkinson’s disease (PD). Published in the British Medical Journal, the PD-COMM trial has been evaluating the effectiveness and cost-effectiveness of two forms of SLT for people living with the neurological disease who have self-reported problems with voice or speech. Affecting around 153,000 people in the UK, PD is a neurodegenerative condition in which parts of the brain become progressively damaged, causing problems such as shaking and stiffness. Due to changes in the brain in people with PD, movements in the muscles to generate speech become smaller and less forceful than before, leading to speech and communication problems. Carried out across the UK by NHS Speech and ...
- Source: drugdu
- 76
- July 19, 2024
UK DRI and NHS collaborate on digitally enabled dementia care platform

by Jen Brogan | 10th Jul 2024 | News Around one in five dementia hospitalisations are due to potentially preventable causes The UK Dementia Research Institute (UK DRI), in collaboration with the NHS, aims to conduct a new two-year study to prepare its digitally-enabled dementia care platform, Minder, to be integrated into health and social care services. Funded by LifeArc, the study will enable digital care for people living with dementia while empowering the NHS and social care services to provide care of the highest quality in patients’ own homes. Estimated to affect 944,000 people in the UK, dementia is a general term for the impaired ability to remember, think, or make decisions that affects everyday life. Developed by the UK DRI Centre for Care Research and Technology, Minder is a home monitoring platform that harnesses artificial intelligence (AI) and digital technology and is integrated with public services to detect ...
- Source: drugdu
- 78
- July 12, 2024
SMC accepts Boehringer/Lilly’s Jardiance for CKD within NHS Scotland

The Scottish Medicines Consortium (SMC) has accepted Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) for use within NHS Scotland to treat adult patients living with chronic kidney disease (CKD). The regulator has indicated the therapy for adult CKD patients who are receiving optimised standard care, including angiotensin converting enzyme inhibitors or angiotensin 2 receptor blockers, with either an estimated glomerular filtration rate (eGFR) of 20ml/min/1.73m2 up to 45ml/min/1.73m2 or an eGFR of 45ml/min/1.73m2 up to 90ml/min/1.73m2. Additionally , patients in Scotland in the 45ml to 80ml group will now be eligible to receive Jardiance if they have a urine albumin-to-creatine ratio of 22.6mg/mmol or more or type 2 diabetes (T2D) mellitus. Affecting nearly 850 million people worldwide, CKD is a serious, progressive condition that is caused by decreased kidney function and is often triggered by diabetes, hypertension and glomerulonephritis. Already approved in the EU and US, Jardiance is an oral, ...
- Source: drugdu
- 77
- July 11, 2024
NHS platform announced to accelerate personalised cancer vaccine clinical trials

The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines The NHS has announced that it has treated its first patient in England with a personalised cancer vaccine in a clinical trial as part of NHS England’s new Cancer Vaccine Launch Pad (CVLP). Following the launch of the trial, thousands of cancer patients in England are set to be fast-tracked to access personalised cancer vaccines to help find new life-saving treatments. In partnership with Genomics England, the NHS CVLP will help speed up access to mRNA-personalised cancer vaccine clinical trials for cancer patients while accelerating the development of cancer vaccines as a form of treatment. With 30 hospitals in England already signed up to participate, the scheme intends to collaborate with the pharmaceutical industry to include patients across many cancer types. Taking place in several NHS trusts across the country to treat different types of ...
- Source: drugdu
- 72
- June 4, 2024
NHS announces hospitals will roll out ‘Martha’s Rule’ as part of patient safety initiative

The first phase of the programme will be in place in hospitals across the UK by March 2025 The NHS has announced the roll out of Martha’s Rule across 143 hospital sites across the UK to test its implementation as part of a major patient safety initiative by March 2025. The scheme is named after Martha Mills, who passed away from sepsis at age 13 in 2021 due to a failure to escalate her to intensive care, while her family’s concerns about her condition were not responded to. The aim of Martha’s Rule is to provide a consistent and understandable way for patients and families to seek an urgent review if either their or their loved one’s condition deteriorates and they are concerned this is not being responded to. The rule is made up of three components: firstly, an escalation process will be available 24/7 to enable patients and families ...
- Source: drugdu
- 122
- June 3, 2024
NHS addresses shortage of ethnic organ and blood donors with £600,000 funding

The funding aims to reduce health inequalities in these groups and save more lives The Community Grants Programme led by NHS Blood and Transplant (NHSBT) has dedicated £600,000 to address the shortage of organ and blood donors from black, Asian and mixed ethnic backgrounds. The funding builds on the ongoing commitment by the government and the NHS to address health inequalities for individuals who need life-saving transplants or regular blood transfusions. The Community Grants Programme funds projects led by community, faith or belief organisations to provide greater awareness and support for donations, particularly among black and Asian communities. Furthermore, the scheme aims to inform and recruit more donors of black heritage to treat people with sickle cell disease, the fastest growing blood disorder in the UK, which is more prevalent in people of this heritage. The NHSBT is seeking applications to engage diverse communities across England and Wales and is ...
- Source: drugdu
- 97
- May 23, 2024
NHS reduces long waits for cancer care and achieves faster ambulance responses

For the second month in a row, the NHS has met the 28-day faster diagnosis target for cancer The NHS has announced, for the second month in a row, that it has met the 28-day faster diagnosis target for cancer as well as faster ambulance responses to call outs compared to March 2024. The announcement builds on targeted national support for NHS trusts in reducing variation across the country and speeding up diagnosis for patients, while also bringing down the backlog of patients waiting for diagnosis or treatment from the COVID-19 pandemic. New published data has shown that the number of patients waiting more than 62 days for care is now at its lowest ever since the end of April 2020, reducing by almost 20,000 patients since the post-pandemic peak. In addition, almost 77% of people referred or screened received a definitive diagnosis or were all clear within four weeks, ...
- Source: drugdu
- 169
- May 15, 2024
NHS still faces waiting list challenges

Commenting on the publication today of the NHS monthly performance statistics, Tim Gardner, Assistant Director of Policy at the Health Foundation, said: ‘While the pressure of winter has eased, today’s data shows urgent and emergency care is still feeling the strain. Over 42,000 patients spent more than 12 hours in A&E before being admitted to a bed last month, and 1 in 10 with a serious condition such as a stroke or chest pain waited over an hour for an ambulance. ‘There are some positive signs in areas of cancer care but following several months of progress, the overall waiting list in March 2024 has remained broadly flat. Fewer than expected referrals into specialist care means the recent fall in the waiting list was largely driven by fewer patients joining the list, rather than because substantially more are being treated. The reality is the waiting list is still 7.5 million, ...
- Source: drugdu
- 142
- May 14, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.